This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
MITRA Overzicht aandelen
Develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Belgium, Europe and internationally.
| Sneeuwvlok Score | |
|---|---|
| Waardering | 3/6 |
| Toekomstige groei | 5/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 1/6 |
| Dividenden | 0/6 |
Mithra Pharmaceuticals SA Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | €0.22 |
| 52 Week Hoogtepunt | €2.29 |
| 52 Week Laag | €0.20 |
| Bèta | 0.51 |
| 11 maand verandering | 0% |
| 3 maanden verandering | 0% |
| 1 Jaar Verandering | -90.11% |
| 33 jaar verandering | -98.79% |
| 5 jaar verandering | -99.27% |
| Verandering sinds IPO | -98.19% |
Recent nieuws en updates
Recent updates
Not Many Are Piling Into Mithra Pharmaceuticals SA (EBR:MITRA) Stock Yet As It Plummets 26%
Apr 06
Revenues Working Against Mithra Pharmaceuticals SA's (EBR:MITRA) Share Price Following 39% Dive
Feb 07Party Time: Brokers Just Made Major Increases To Their Mithra Pharmaceuticals SA (EBR:MITRA) Earnings Forecasts
Nov 09These Analysts Just Made A Huge Downgrade To Their Mithra Pharmaceuticals SA (EBR:MITRA) EPS Forecasts
Oct 05Take Care Before Diving Into The Deep End On Mithra Pharmaceuticals SA (EBR:MITRA)
May 23Bullish: Analysts Just Made A Huge Upgrade To Their Mithra Pharmaceuticals SA (EBR:MITRA) Forecasts
Aug 11Growth Investors: Industry Analysts Just Upgraded Their Mithra Pharmaceuticals SA (EBR:MITRA) Revenue Forecasts By 21%
Mar 13Mithra Pharmaceuticals (EBR:MITRA) Is Making Moderate Use Of Debt
Dec 22Some Mithra Pharmaceuticals SA (EBR:MITRA) Analysts Just Made A Major Cut To Next Year's Estimates
Nov 24Here's Why Mithra Pharmaceuticals (EBR:MITRA) Can Afford Some Debt
Jun 07When Will Mithra Pharmaceuticals SA (EBR:MITRA) Turn A Profit?
May 10Is Mithra Pharmaceuticals SA's (EBR:MITRA) Shareholder Ownership Skewed Towards Insiders?
Mar 18We're Not So Sure You Should Rely on Mithra Pharmaceuticals' (EBR:MITRA) Statutory Earnings
Feb 16Analysts Expect Breakeven For Mithra Pharmaceuticals SA (EBR:MITRA) Before Long
Jan 21
Some Mithra Pharmaceuticals SA (EBR:MITRA) Analysts Just Made A Major Cut To Next Year's Estimates
Nov 29Rendement voor aandeelhouders
| MITRA | BE Pharmaceuticals | BE Markt | |
|---|---|---|---|
| 7D | 0% | -2.8% | -3.2% |
| 1Y | -90.1% | 10.7% | 7.7% |
Rendement versus industrie: MITRA presteerde slechter dan de Belgian Pharmaceuticals -sector, die het afgelopen jaar een rendement van 10.7 % opleverde.
Rendement versus markt: MITRA presteerde slechter dan Belgian Market, dat het afgelopen jaar een rendement van 7.7 % opleverde.
Prijsvolatiliteit
| MITRA volatility | |
|---|---|
| MITRA Average Weekly Movement | 0% |
| Pharmaceuticals Industry Average Movement | 5.1% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in BE Market | 6.5% |
| 10% least volatile stocks in BE Market | 2.3% |
Stabiele aandelenkoers: MITRA heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.
Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van MITRA in het afgelopen jaar te bepalen.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1999 | 270 | Christophe Marechal | www.mithra.com |
Mithra Pharmaceuticals SA Samenvatting
| MITRA fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | €12.14m |
| Inkomsten(TTM) | -€173.50m |
| Inkomsten(TTM) | €40.16m |
0.4x
P/S-verhouding-0.1x
Koers/WinstverhoudingIs MITRA overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| MITRA resultatenrekening (TTM) | |
|---|---|
| Inkomsten | €40.16m |
| Kosten van inkomsten | €21.95m |
| Brutowinst | €18.21m |
| Overige uitgaven | €191.71m |
| Inkomsten | -€173.50m |
Laatst gerapporteerde inkomsten
Dec 31, 2023
Volgende inkomensdatum
Sep 26, 2024
| Winst per aandeel (EPS) | -2.51 |
| Brutomarge | 45.34% |
| Nettowinstmarge | -432.08% |
| Schuld/Eigen Vermogen Verhouding | -258.9% |
Hoe presteerde MITRA op de lange termijn?
Bekijk historische prestaties en vergelijking